Table 3: Ranking for all the outcomes of the interventions included at 12 or 16 weeks in the network meta-analysis.

InterventionsPASI 75PASI 100sPGA 0/1 or IGA 0/1 or PGA 0/1AEssAEsDiscontinuations due to AEs
SUCRA (%)PrBestMeanRankSUCRA (%)PrBestMeanRankSUCRA (%)PrBestMeanRankSUCRA (%)PrHighest riskMeanRankSUCRA (%)PrHighest riskMeanRankSUCRA (%)PrHighest riskMeanRank

Brodalumab 140 mg22.
Brodalumab 210 mg62.50.35.985.028.42.965.40.15.523.70.010.963.93.85.763.00.95.8
Guselkumab 100 mg28.50.010.361.
Guselkumab 50 mg38.
Ixekizumab 80 mg Q2W93.053.41.983.332.73.286.513.
Ixekizumab 80 mg Q4W81.50.53.476.812.
Risankizumab 150 mg62.30.45.971.36.44.766.70.45.367.
Secukinumab 150 mg73.50.04.4310.
Secukinumab 300 mg89.943.12.362.48.35.998.186.01.333.90.09.635.60.99.442.20.18.5
Tildrakizumab 100 mg33.20.29.721.90.411.
Tildrakizumab 200 mg42.21.78.520.00.011.434.70.29.590.231.32.341.11.28.735.40.49.4
Ustekinumab 45 mg27.40.010.433.10.09.725.40.010.741.00.08.761.
Ustekinumab 90 mg44.

SUCRA: surface under the cumulative ranking; PrBest: probability of best treatment; PrHighest risk: probability of the highest risk of AEs; PASI 75: the percentages of patients with a 75% improvement from baseline in the PASI score; PASI 100: the percentages of patients with a 100% improvement from baseline in the PASI score; sPGA 0/1: static physician’s global assessment score 0 or 1; IGA 0/1: a response of 0 or 1 on the modified investigator’s global assessment; PGA 0/1: physician’s global assessment score of 0 or 1; AEs: adverse events; sAEs: serious adverse events; Q2W: every 2 weeks; Q4W: every 4 weeks.